Occurrence of cervical infection with multiple human papillomavirus types is associated with age and cytologic abnormalities

Sexually Transmitted Diseases

Volumn 30, Issue 7, 2003, Pages 581-587

  Rousseau, Marie Claude ^a   Villa, Luisa L ^b   Costa, Maria Cecilia ^b   Abrahamowicz, Michal ^a,c   Rohan, Thomas E ^d   Franco, Eduardo ^a  

^a MCGILL UNIVERSITY   (Canada)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Brazil)

^c MONTREAL GENERAL HOSPITAL   (Canada)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ADULT; AGING; ARTICLE; BRAZIL; COHORT ANALYSIS; DISEASE ASSOCIATION; FEMALE; HUMAN; INFECTION CONTROL; MAJOR CLINICAL STUDY; NONHUMAN; POLYMERASE CHAIN REACTION; PREVALENCE; RISK FACTOR; SEXUALLY TRANSMITTED DISEASE; UTERINE CERVICITIS; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VACCINATION; VIRUS DETECTION; VIRUS INFECTION; WART VIRUS;

EID: 0038336863     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007435-200307000-00010     Document Type: Article

References (36)

1. IARC Working Group. Human Papillomaviruses. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 64. Lyon: World Health Organization, International Agency for Research on Cancer, 1995.
2. Walboomers JMM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189(1):12-19.
3. Lorincz AT, Reid R, Jenson AB, Greenberg MD, Lancaster W, Kurman RJ. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol 1992; 79:328-337.
4. Sasagawa T, Basha W, Yamazaki H, Inoue M. High-risk and multiple human papillomavirus infections associated with cervical abnormalities in Japanese women. Cancer Epidemiol Biomarkers Prev 2001; 10(1):45-52.
5. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55:244-265.
6. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 1995; 87:796-802.
7. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999; 80:827-841.
8. Roden RB, Greenstone HL, Kirnbauer R, et al. In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J Virol 1996; 70:5875-5883.
9. Unckell F, Streeck RE, Sapp M. Generation and neutralization of pseudovirions of human papillomavirus type 33. J Virol 1997; 71: 2934-2939.
10. White WI, Wilson SD, Bonnez W, Rose RC, Koenig S, Suzich JA. In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16. J Virol 1998; 72:959-964.
11. Schiller JT, Hildesheim A. Developing HPV virus-like particle vaccines to prevent cervical cancer: a progress report. J Clin Virol 2000; 19:67-74.
12. Da Silva DM, Eiben GL, Fausch SC, et al. Cervical cancer vaccines: emerging concepts and developments. J Cell Physiol 2001; 186: 169-182.
13. Schiller JT, Lowy DR. Papillomavirus-like particle vaccines. J Natl Cancer Inst Monogr 2000; 28:50-54.
14. Schiller JT. Papillomavirus-like particle vaccines for cervical cancer. Mol Med Today 1999; 5:209-215.
15. Kols A, Sherris J. HPV Vaccines: Promise and Challenges. Updated July 2000. URL: http://www.path.org/Files/jsrp13710.pdf, accessed July 2002.
16. Franco E, Villa L, Rohan T, Ferenczy A, Petzl-Erler M, Matlashewski G. Design and methods of the Ludwig-McGill longitudinal study of the natural history of human papillomavirus infection and cervical neoplasia in Brazil. Ludwig-McGill Study Group. Rev Panam Salud Publica 1999; 6:223-233.
17. Bauer HM, Ting Y, Greer CE, et al. Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA 1991; 265:472-477.
18. Hildesheim A, Schiffman MH, Gravitt PE, et al. Persistence of typespecific human papillomavirus infection among cytologically normal women. J Infect Dis 1994; 169:235-240.
19. Bernard HU, Chan SY, Manos MM, et al. Identification and assessment of known and novel human papillomaviruses by PCR amplification, restriction fragment length polymorphisms, nucleotide sequence, and phylogenetic algorithms. J Infect Dis 1994; 170:1077-1085.
20. Thomas KK, Hughes JP, Kuypers JM, et al. Concurrent and sequential acquisition of different genital human papillomavirus types. J Infect Dis 2000; 182:1097-1102.
21. Abramson JH; Gahlinger PM. Computer Programs for Epidemiologists: PEPI Version 4.0. Salt Lake City: Sagebrush Press, 2001.
22. Ho GY, Palan PR, Basu J, et al. Viral characteristics of human papillomavirus infection and antioxidant levels as risk factors for cervical dysplasia. Int J Cancer 1998; 78:594-599.
23. Herrero R, Hildesheim A, Bratti C, et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 2000; 92:464-474.
24. Castellsague X, Menendez C, Loscertales MP, et al. Human papillomavirus genotypes in rural Mozambique. Lancet 2001; 358(9291): 1429-1430.
25. Fife KH, Cramer HM, Schroeder JM, Brown DR. Detection of multiple human papillomavirus types in the lower genital tract correlates with cervical dysplasia. J Med Virol 2001; 64:550-559.
26. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518-527.
27. van der Graaf Y, Molijn A, Doornewaard H, Quint W, van Doorn LJ, van den Tweel J. Human papillomavirus and the long-term risk of cervical neoplasia. Am J Epidemiol 2002; 156:158-164.
28. Ley C, Bauer HM, Reingold A, et al. Determinants of genital human papillomavirus infection in young women. J Natl Cancer Inst 1991; 83:997-1003.
29. Morrison EA, Ho GY, Vermund SH, et al. Human papillomavirus infection and other risk factors for cervical neoplasia: a case-control study. Int J Cancer 1991; 49:6-13.
30. Melkert PWJ, Hopman E, van den Brule AJC, et al. Prevalence of HPV in cytomorphologically normal cervical smears, as determined by the polymerase chain reaction, is age-dependent. Int J Cancer 1993; 53:919-923.
31. Burk RD, Kelly P, Feldman J, et al. Declining prevalence of cervicovaginal human papillomavirus infection with age is independent of other risk factors. Sex Transm Dis 1996; 23:333-341.
32. Wideroff L, Schiffman M, Haderer P, et al. Seroreactivity to human papillomavirus types 16, 18, 31, and 45 virus-like particles in a case-control study of cervical squamous intraepithelial lesions. J Infect Dis 1999; 180:1424-1428.
33. Combita AL, Bravo MM, Touze A, Orozco O, Coursaget P. Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58 and 59 virus-like particles in Colombian women with invasive cervical cancer. Int J Cancer 2002; 97:796-803.
34. Liaw KL, Hildesheim A, Burk RD, et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis 2001; 183(1):8-15.
35. Rousseau MC, Pereira JS, Prado JC, Villa LL, Rohan TE, Franco EL. Cervical coinfection with human papillomavirus (HPV) types as a predictor of acquisition and persistence of HPV infection. J Infect Dis 2001; 184:1508-1517.
36. Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000; 38:357-361.